We note the recent debate piece (Bastiampillai et al., 2018) highlighting concerns about the potential implications of prescribing antipsychotic medication in paediatric populations, due to the potential risks of antipsychotic-induced brain atrophy. Worldwide antipsychotic medications are increasingly being prescribed for the maintenance treatment of bipolar affective disorder (BPAD) in preference to mood-stabilising medication like lithium. Lithium use is declining despite being the gold standard treatment for the maintenance phase of BPAD.
- prescribing antipsychotic medication
- antipsychotic-induced brain atrophy
- bipolar affective disorder (BPAD)
- maintenace phase of BPAD
Elangovan, S., Bastiampillai, T., Kanigere, M., Kulkarni, S., & Tibrewal, P. (2019). Antipsychotic-induced brain atrophy: Is lithium the answer in bipolar disorder? Australian and New Zealand Journal of Psychiatry, 53(9), 925-926. https://doi.org/10.1177/0004867419865393